Serina Therapeutics, Inc. (SER)

In January 2026, Serina Therapeutics announced that the FDA cleared its IND application for SER-252 for the treatment of advanced Parkinson's disease. In October 2025, Serina Therapeutics launched an enhanced corporate communications platform. In September 2025, the company received up to $20 million in funding to support a Phase 1b study for SER-252. In August 2025, Serina Therapeutics announced the advancement of SER-270 (POZ-VMAT2i) into development for Tardive Dyskinesia (TD).

Based on the provided information, there is no indication of demand seasonality for Serina Therapeutics' products and services. Demand is primarily driven by disease prevalence, clinical trial outcomes, regulatory approvals, and market adoption.

Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing drugs to treat neurological diseases and pain, utilizing its proprietary POZ Platform™ drug optimization technology. Their lead product candidate is SER-252 (POZ-apomorphine) for advanced Parkinson's disease, anticipated to enter clinical trials in the fourth quarter of 2025, with FDA clearance of its IND application in January 2026. Other product candidates include SER-270 (POZ-VMAT2i) for tardive dyskinesia, SER-227 for long-acting pain relief, SER-214 for early Parkinson's and Restless Leg Syndrome, and SER-228 for epilepsy. The company is also developing POZ technology in lipid nanoparticle-delivered ribonucleic acid vaccines for infectious diseases.

Serina Therapeutics, Inc. is based in Huntsville, Alabama, United States, on the campus of the HudsonAlpha Institute of Biotechnology. The registrational study for SER-252 is planned to be conducted across sites in the U.S. and Australia.

In the past year, Serina Therapeutics has focused on enhancing its communication and transparency by launching a comprehensive corporate communications platform on October 8, 2025, to provide timely updates to stakeholders. This initiative includes program and clinical updates, educational resources, multimedia content, and opportunities for engagement.

As of January 29, 2026, insider ownership of Serina Therapeutics, Inc. was -0.06%. Insider transactions in 2024 included several purchases by Gregory Bailey and Steven Mintz, and a sale by Srini Tenjarla. Greg Bailey led a financing round of up to $20 million in September 2025.